High Content Screening company Cellomics announced today that the Canadian Intellectual Property Office has issued Cellomics' Canadian Patent No. 2,328,194 entitled 'A System for Cell-Based Screening.'
The patent encompasses methods for High Content Screening (HCS), including methods and software for cell-based detection and classification of receptor internalisation events. The claims include methods of measuring the localisation, distribution or activity of fluorescent reporter molecules to detect the internalisation of receptors, whether the receptor constitutively expresses fluorescence or is exogenously labelled.
"Effective monitoring of internalisation events, as surrogates of receptor activation or in kinetic investigations, is the cornerstone of many drug discovery programs as well as a major focus of research in the life sciences.
This patent strengthens our already extensive portfolio of proprietary BioApplications, methods and reagents that, together with the rest of our powerful HCS platform, enable our users to quickly integrate receptor internalisation evaluations into their research," said Dr. Jeffrey Haskins, vice president of assay development with Cellomics.
"We believe that this patent, along with our four other issued patents and greater than 40 patents pending on broad HCS methods, specific BioApplications, reagents, instrumentation, tools for information management and cellular bioinformatics will further our dominant IP position in HCS," added D. Lansing Taylor, chairman and CEO.